Skip to content
Clinical Trials – home
Institut fuer Klinische Krebsforschung IKF GmbH
Sponsor

Institut fuer Klinische Krebsforschung IKF GmbH

Germany Steinbacher Hohl 2-26, Praunheim, 60488 Frankfurt, Germany

About the sponsor

Gastroesophageal adenocarcinoma, gastric cancer, and colorectal cancer are central areas of interest, alongside multiple biliary tract cancers and cholangiocarcinoma subtypes. The portfolio also includes hepatocellular carcinoma across intermediate, advanced, and unresectable disease settings.

  • Intrahepatic cholangiocarcinoma
  • Extrahepatic cholangiocarcinoma
  • Metastatic colorectal cancer
  • Advanced hepatocellular carcinoma
  • Esophagogastric adenocarcinoma

Research activity also covers biomarker-defined disease groups, including FGFR2-altered and HER2-positive tumors in the upper gastrointestinal tract.

About Specializations

Institut fuer Klinische Krebsforschung IKF GmbH runs clinical trials in conditions such as Cholangiocarcinoma, Gastrooesophageal cancer, Oesophageal adenocarcinoma, Hepatocellular carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

31 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.